GreenRoc Accelerates their World Class Project to Production as Early as 2028. Watch the full video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Share News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,516.00
Bid: 12,554.00
Ask: 12,556.00
Change: 0.00 (0.00%)
Spread: 2.00 (0.016%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 12,516.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

LONDON BRIEFING: Lower open ahead of BoE, ECB; Currys swings to loss

Thu, 15th Dec 2022 07:49

(Alliance News) - Stock prices in London are set to open lower on Thursday, after the US Federal Reserve raised interest rates as expected and ahead of three more central bank decisions.

The Fed hiked rates by 50 basis points, as widely expected, but also forecast that interest rates will peak at a higher level than previously expected.

The Federal Open Market Committee lifted the target range for the federal funds rate to 4.25% to 4.50% - the highest since 2007 - from the previous range of 3.75% to 4.00%.

"The committee anticipates that ongoing increases in the target range will be appropriate in order to attain a stance of monetary policy that is sufficiently restrictive to return inflation to 2% over time," the Fed explained.

The Swiss National Bank will kick off Thursday's busy day for central bank decisions at 0830 GMT, before the Bank of England announces its interest rate decision at midday, followed shortly afterward by the European Central Bank.

China's retail sales plunged last month, official data showed, as Covid restrictions and a property market crisis hammered the world's second-largest economy.

The figures highlight the work ahead for the government as it moves away from almost three years of strict containment measures that have whittled growth and sent shudders through supply chains.

November retail sales sank 5.9% year-on-year, marking the second successive contraction, according to data released by the National Bureau of Statistics.

In early company news in London, electronics retailer Currys fell into a half-year loss, due to an impairment. Outsourcer Serco raised its 2022 guidance, and oil field services provider Hunting raised 2023 guidance.

Here is what you need to know ahead of the London market open:

----------

MARKETS

----------

FTSE 100: called down 27.63 points, or 0.4%, at 7,468.30

----------

Hang Seng: down 1.5% at 19,373.22

Nikkei 225: closed down 0.4% at 28,051.70

S&P/ASX 200: closed down 0.6% at 7,204.80

----------

DJIA: closed down 0.4%, at 33,966.35

S&P 500: closed down 0.6% at 3,995.32

Nasdaq Composite: closed down 0.8% at 11,170.89

----------

EUR: lower at USD1.0652 (USD1.0660)

GBP: lower at USD1.2387 (USD1.2410)

USD: higher at JPY135.77 (JPY134.82)

Gold: lower at USD1,792.36 per ounce (USD1,810.74)

(Brent): lower at USD82.00 a barrel (USD82.51)

(changes since previous London equities close)

----------

ECONOMICS

----------

Thursday's key economic events still to come:

14:15 CET EU ECB interest rate announcement

11:00 GMT Ireland goods exports and imports

12:00 GMT UK BoE MPC meeting minutes

12:00 GMT UK interest rate decision

08:30 EST US advance monthly sales for retail and food services

08:30 EST US Philadelphia Fed business outlook survey

08:30 EST US unemployment insurance claims report

08:30 EST US weekly export sales

09:15 EST US industrial production

16:00 EST US treasury international capital data

16:30 EST US Foreign Central Bank holdings

16:30 EST US federal discount window borrowings

----------

Tens of thousands of nurses are going on strike for the first time across England, Wales and Northern Ireland. Picket lines are being set up at dozens of hospitals in a dispute over pay, with the Welsh government saying services will be "significantly impacted". Thousands of NHS appointments and operations have been cancelled because of the strike, with the health service running a bank holiday-style service in many areas. The Royal College of Nursing has said it will still staff chemotherapy, emergency cancer services, dialysis, critical care units, neonatal and paediatric intensive care. Some areas of mental health and learning disability and autism services are also exempt, while trusts have been told they can request staffing for specific clinical needs. When it comes to adult A&E and urgent care, nurses will work Christmas Day-style rotas.

----------

BROKER RATING CHANGES

----------

Deutsche Bank raises AstraZeneca price target to 13,000 (12,000) pence - 'buy'

----------

Goldman Sachs raises Big Yellow to 'buy' ('neutral') - price target 1,250 (1,130) pence

----------

Barclays raises Victorian Plumbing to 'overweight' ('equal-weight') - price target 100 (75) pence

----------

COMPANIES - FTSE 100

----------

Pharmaceutical firm AstraZeneca, alongside US peer Merck & Co, announced that the US Food & Drug Administration will extend the Prescription Drug User Fee Act date by three months to allow further time for a full review of the supplementary new drug application of Lynparza in combination with abiraterone and prednisone or prednisolone. The review is for Lynparza in combination for the treatment of metastatic castration-resistant prostate cancer.

----------

SSE's SSEN Transmission arm welcomed UK Ofgem's approval of transmission investments needed to meet the UK government's 50 gigawatt offshore wind target by 2030. The electricity provider said the decision by the regulator confirms that all SSEN transmission projects will be taken forward as part of the Accelerated Strategic Transmission Investment framework. As a result, two 2 gigawatt subsea high-voltage direct current links will be taken forward as joint ventures with National Grid Electricity Transmission, amongst other projects. Ofgem also confirmed these will be exempt from proposals to introduce competitive ownership of onshore electricity networks. National Grid said it welcomed the clarity that the Ofgem decision gives to NGET. Ofgem said the ASTI framework streamlines the onshore transmission regulatory approval process in the UK.

----------

COMPANIES - FTSE 250

----------

Currys swung sharply to a loss in the six months ended October 29, as revenue declined. The electricals retailer posted a pretax loss of GBP548 million, swinging from a profit of GBP48 million in the previous year. Revenue fell to GBP4.47 billion from GBP4.79 million. More significantly, Currys booked an impairment of goodwill of GBP511 million in the half-year, compared to no such impairment a year before. It said this arose at the time of the Dixons Carphone merger in 2014. Currys also noted lower international profits and margin for the swing to a loss. The company now expects full-year pretax profit to be between GBP100 million and GBP125 million. In the first six weeks of the second half, trading has been in-line with the first half.

----------

Outsourcer Serco said it expects its 2022 results to be "slightly" ahead of previous guidance and added its 2023 results are due to be in-line with expectations. Revenue for 2022 is expected at GBP4.5 billion, Serco said, slightly above 2021 despite a reduction in Covid-related revenue. Underlying trading profit is expected at GBP235 million, representing a GBP5 million increase on the firm's previous guidance. For 2023, underlying trading profit is expected to be similar to 2022 at GBP235 million. Chief Executive Rupert Soames said: "2022 will turn out much better than we expected at the start of the year as strong growth across the business largely replaced Covid contracts. Revenue is expected to be 8% higher and underlying trading profit around 20% better than we anticipated when we first gave guidance in December 2021." Soames steps down at the end of the year, replaced by Mark Irwin, currently CEO of Serco's UK & Europe business.

----------

OTHER COMPANIES

----------

Hunting said that its 2022 trading and financial outturn remains in-line with market expectations, with earnings before interest, tax, depreciation and amortisation predicted at USD50 million. The oil and gas industry services provider added that its sales order book continues to improve, with the order book now approaching USD500 million. For 2023, Hunting raised guidance for Ebitda to between USD85 million and USD90 million, up from USD80 million previously. Chief Executive Jim Johnson said: "2022 has been a year of rebuilding for the industry with 2023 now likely to be a strong year of growth for the group. All of our operating segments are reporting good levels of enquiries, and with our order book now approaching USD500 million, our earnings visibility for the year ahead is robust, despite recessionary fears."

----------

By Heather Rydings, Alliance News senior economics reporter

Comments and questions to newsroom@alliancenews.com

Copyright 2022 Alliance News Ltd. All Rights Reserved.

More News
22 Dec 2023 07:17

AstraZeneca gets FDA green light for nerve disease treatment

(Sharecast News) - The US Food and Drug Administration has approved the Wainua nerve disease treatment jointly developed by AstraZeneca and Ionis Pharmaceuticals.

Read more
19 Dec 2023 19:56

US adds 13 companies in China to Unverified List

WASHINGTON, Dec 19 (Reuters) - The United States has added 13 companies in China to a list of entities receiving U.S. exports that officials have been unable to inspect, according to a government notice posted on Tuesday.

Read more
15 Dec 2023 17:14

London stocks log weekly gains as cenbank fest ends

FTSE 100 down 1.0%, FTSE 250 off -0.3%

*

Read more
15 Dec 2023 16:51

LONDON MARKET CLOSE: FTSE 100 underperforms as post-Fed rally cools

(Alliance News) - London's FTSE 100 ended lower on Friday, with profit-taking and some hawkish words from a US policymaker keeping equities in check at the end of a largely positive week for stocks.

Read more
15 Dec 2023 16:29

PRESS: GSK, Astra and AbbVie in US scrutiny over patents - Bloomberg

(Alliance News) - A US senator has accused AstraZeneca PLC, GSK PLC, AbbVie Inc and other drugmakers of "abusing" the patent system to send prices higher, Bloomberg reported on Thursday.

Read more
13 Dec 2023 17:07

UK's FTSE 100 rises as pound slips on GDP data; awaits Fed rate decision

UK economy shrinks by 0.3% in October

*

Read more
12 Dec 2023 16:00

London close: Stocks slip as investors digest US inflation

(Sharecast News) - London's markets finished in the red on Tuesday, as investors digested a slight decrease in consumer inflation in the US, while the UK's unemployment figures remained stable.

Read more
12 Dec 2023 12:07

London midday: FTSE still firmer ahead of US inflation print

(Sharecast News) - London's markets remained relatively stable by midday on Tuesday, with the top-flight index still in the green after fresh jobs data showed a slowdown in wage growth.

Read more
12 Dec 2023 10:08

AstraZeneca buys respiratory vaccine developer Icosavax in $1.1 bln deal

Dec 12 (Reuters) - AstraZeneca said on Tuesday it had agreed to buy respiratory syncytial virus (RSV) vaccine developer Icosavax in a deal valued at up to $1.1 billion.

Read more
12 Dec 2023 08:53

LONDON MARKET OPEN: FTSE 100 opens higher ahead of US CPI

(Alliance News) - Stock prices in London opened higher on Tuesday, as investors digest the latest UK unemployment data, before turning their eyes to US inflation this afternoon.

Read more
12 Dec 2023 08:37

AstraZeneca acquires vaccine developer Icosavax for USD1.1 billion

(Alliance News) - AstraZeneca PLC confirmed on Tuesday that it will buy Icosavax Inc, boosting its vaccine portfolio with an "innovative" treatment for respiratory viruses.

Read more
12 Dec 2023 07:39

LONDON BRIEFING: UK unemployment unchanged at 4.2%; eyes on US CPI

(Alliance News) - Stocks in London are called to open higher, as investors digest the latest UK unemployment data, before turning their heads to US inflation.

Read more
12 Dec 2023 07:16

AstraZeneca to buy US vaccine maker Icosavax for up to $1.1bn

(Sharecast News) - AstraZeneca said on Tuesday that it has agreed to buy Icosavax - a US-based clinical-stage biopharmaceutical company - for up to $1.1bn.

Read more
12 Dec 2023 02:00

UK companies pause China investment decisions as economy slows, survey shows

BEIJING, Dec 12 (Reuters) - A slowdown in both the Chinese and global economies is the biggest issue affecting British firms in the world's second-largest economy, beating geopolitical concerns and market access barriers, according to the British Chamber of Commerce in China.

Read more
11 Dec 2023 08:15

AstraZeneca says danicopan tests well as blood disorder treatment

(Alliance News) - AstraZeneca PLC on Monday reported "positive results" from a test of danicopan for the treatment of paroxysmal nocturnal haemoglobinuria, or PNH, a rare and severe blood disorder.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.